Viewing nowBielglime Tablet 2 mg (Glymepiride)
Glimepiride 2mg
Tablet · Prescription medication
Sears Pharmaceutical Co., Ltd.

MFDS item code 201801327 · Approved 2018.03.27 · Insurance code 689000330
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes, in conjunction with dietary and exercise therapy. It can be administered alone or in combination with other oral hypoglycemic agents or insulin. Especially in cases where blood sugar control is not adequately achieved with sulfonylureas or metformin, this medication is added to enhance treatment effects. This medication plays an important role in improving blood sugar control.
The dose should be adjusted individually for each patient. Swallow whole without chewing with at least 1/2 glass of water. This drug is administered orally once daily. Take this drug before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this drug. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received medication, start treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, but some patients have achieved better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this drug may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, changes in lifestyle, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral antihyperglycemic agent to this drug There is no exact dose equivalence between this drug and other oral antihyperglycemic agents. When switching from another oral antihyperglycemic agent to this drug, it is advisable to follow the instructions provided under Initial Dose. That is, start at 1 mg daily and adjust the dose at intervals of 1 ~ 2 weeks. The potency and duration of action of the previous medication should be considered. 4) Dose monitoring While taking this drug, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Hypoglycemia may recur despite successful initial management when a sulfonylurea is administered. Therefore, patients should be carefully monitored. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this drug and insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this drug once daily with the first meal; start insulin at a low dose and increase it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin dosage should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, adding metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for glycemic control. There is a risk of hypoglycemia when this drug is administered with metformin, and the risk may be increased. Appropriate caution should be exercised.
This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or in a coma. Additionally, patients who have had hypersensitivity reactions to this medication, its components, sulfonylureas, or sulfonamide medications should not take this product. In cases of severe liver or kidney dysfunction, switching to insulin treatment is recommended instead of using this medication. Pregnant women, women who may become pregnant, and breastfeeding women should also avoid taking this medication. Patients with severe infections, undergoing surgery, or in a state of serious trauma should receive insulin treatment instead of this medication. Patients with gastrointestinal disturbances such as diarrhea or vomiting should be cautious, as these can lead to problems with food absorption and increase the risk of hypoglycemia. This medication contains lactose, so patients with galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it. During the first week of dosing, the risk of hypoglycemia is higher, so careful monitoring of blood sugar levels is essential. Patients with poor nutritional status, irregular meal patterns, or imbalances in physical activity and carbohydrate intake are at greater risk for hypoglycemia. Caution is also advised for patients who consume alcohol, have decreased kidney and liver function, elderly patients, and those with certain endocrine disorders, as they may have an increased risk of hypoglycemia. When taking this medication with other drugs, interactions may occur; therefore, it is crucial to inform your doctor or pharmacist about any other medications being taken. This medication contains Yellow No. 4 (Tartrazine) and should be used with caution in patients allergic to this component. Hypoglycemic symptoms may arise while taking this medication, so if symptoms such as headache, severe hunger, nausea, fatigue, confusion, drowsiness, or loss of consciousness occur, it is crucial to consume sugar immediately and inform medical staff. Temporary blurred vision or visual disturbances may occur, and gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea may develop. Liver dysfunction or blood-related adverse reactions may rarely occur, so immediate consultation with medical personnel is necessary if unusual symptoms arise. Allergic reactions such as itching, rash, or difficulty breathing may occur, and in severe cases may progress to shock, so caution is needed. This medication must be taken regularly, and optimal blood sugar control requires adherence to dietary and exercise therapy. In case of hypoglycemia, it is important to rapidly ingest foods or beverages containing sugar, as artificial sweeteners do not help control hypoglycemia. Pregnant or breastfeeding women should not take this medication and should switch to insulin treatment for safety. The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age, thus it should not be used in this population. In cases of overdose, severe hypoglycemia may occur, necessitating immediate medical care.
Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disorders, anxiety, aggression, decreased concentration, decreased agility or motivation, depression, confusion, language abnormalities, aphasia, visual impairment, tremors, incomplete paralysis, sensory disturbances, dizziness, weakness, loss of self-control, temporary mental confusion, seizures, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina, deep vein thrombosis, blurred vision, fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased liver enzymes, liver dysfunction, biliary secretion disorder, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis, pancytopenia, itching, urticaria, rash, dyspnea, hypotension, shock, anaphylaxis, angioedema, skin and mucosal syndrome, allergic vasculitis, phototoxic reactions of the skin, decreased serum sodium concentration, taste disturbances, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, joint pain, dyspepsia, facial edema, erectile dysfunction, facial flushing, gastritis
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is important to maintain storage temperatures between 1°C to 30°C to preserve the medication's efficacy and safety for an extended period.
Green rectangular tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowGlimepiride 2mg
Tablet · Prescription medication
Sears Pharmaceutical Co., Ltd.

Glimepiride 1mg
Tablet · Prescription medication
Handok Co., Ltd.

Glimepiride 2mg
Tablet · Prescription medication
Handok Co., Ltd.

Glimepiride 4mg
Tablet · Prescription medication
(Hanmi Pharmaceutical Co., Ltd.)

Glimepiride 2mg
Tablet · Prescription medication
Seoul Pharmaceutical Co., Ltd.

Glimepiride 2mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Glimepiride 2mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Glimepiride 2mg
Tablet · Prescription medication
IYun Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.